Skip to Main Content
Table 3.

Grade 2 and above AEs at least possibly related to neratinib (N = 16)

AEGrade 2, N (%)Grade 3, N (%)Total, N (%)
Diarrhea 7 (44%) 4 (25%)* 11 (69%) 
Anorexia 7 (44%) 7 (44%) 
Fatigue 4 (25%) 1 (6%) 5 (31%) 
Anemia 3 (19%) 3 (19%) 
Nausea 3 (19%) 3 (19%) 
Dehydration 1 (6%) 1 (6%) 2 (13%) 
Dyspepsia 2 (13%) 2 (13%) 
Hypophosphatemia 2 (13%) 2 (13%) 
Vomiting 2 (13%) 2 (13%) 
Syncope 1 (6%) 1 (6%) 
AEGrade 2, N (%)Grade 3, N (%)Total, N (%)
Diarrhea 7 (44%) 4 (25%)* 11 (69%) 
Anorexia 7 (44%) 7 (44%) 
Fatigue 4 (25%) 1 (6%) 5 (31%) 
Anemia 3 (19%) 3 (19%) 
Nausea 3 (19%) 3 (19%) 
Dehydration 1 (6%) 1 (6%) 2 (13%) 
Dyspepsia 2 (13%) 2 (13%) 
Hypophosphatemia 2 (13%) 2 (13%) 
Vomiting 2 (13%) 2 (13%) 
Syncope 1 (6%) 1 (6%) 

NOTE: AEs that are grade 2 or above experienced by more than one patient or any occurrence of grade 3 AEs are included.

Close Modal

or Create an Account

Close Modal
Close Modal